Jason Zell is an Oncology physician affiliated with University of California, Irvine. OpenAlex indexes 212 publications with 5,266 citations (h-index 38); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
101 The City Dr S
Orange, CA 928683201
Telephone
714-456-8068Registry record last updated 10 Jul 2007.
Clinical trials
- S0820, Adenoma and Second Primary Prevention Trial
Sponsor: SWOG Cancer Research Network
- Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI
Sponsor: National Cancer Institute (NCI)
- Trial of Aspirin and Arginine Restriction in Colorectal Cancer
Sponsor: University of California, Irvine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
49%Nucleoside Analog Antiviral49%Lonsurf100%Part D<11 patientsNervous system
26.5%Phenothiazine26.5%Prochlorperazine Maleate100%Part D<11 patientsMetabolism & gastrointestinal
24.5%Serotonin-3 Receptor Antagonist24.5%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2009–2025 per NIH RePORTER. The latest:
- Advancing novel cancer preventive and therapeutic strategies across the modern NCI clinical trial networks
University of California-Irvine
FY2025$196,267R50CA285412 - Advancing novel cancer preventive and therapeutic strategies across the modern NCI clinical trial networks
University of California-Irvine
FY2024$196,267R50CA285412 - Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and Liver Cancer (CLOVER)
University of California at Davis
FY2021$293,756R61AG068948
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Susan O’Brien, MD
University of California, Irvine
Steven Potkin, MD
University of California, Irvine
Mitchell Brin, MD
University of California, Irvine
Deborah Wing, MD
University of California, Irvine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”